OS Therapies confirmed a September 30, 2026 BLA submission window for OST-HER2 in osteosarcoma, with an FDA Type B pre-BLA meeting approaching. The company is simultaneously advancing an Australian Phase 3 launch and monitoring an EMA CMAA filing window, while confirming capital sufficiency through 2027.
Key Highlights
- BLA Window Secured: September 30, 2026 BLA submission window confirmed for OST-HER2 (AOST-2121) in resected osteosarcoma with FDA Type B pre-BLA meeting in early autumn 2026.
- Global Regulatory Coordination: EMA CMAA filing window opens by September 30, 2026, alongside an Australian Phase 3 launch, reflecting coordinated multi-jurisdictional regulatory strategy.
- Funded Through 2027: Existing capital confirmed sufficient to fund operations through 2027, providing balance sheet clarity through the BLA submission period without near-term equity raise risk.
OST-HER2 and the Osteosarcoma Treatment Gap
Osteosarcoma is a rare primary bone malignancy that disproportionately affects adolescents and young adults, with a bimodal age distribution peaking in the second decade and again in the sixth decade of life. Despite decades of clinical research, the chemotherapy regimens used to treat high-grade localised osteosarcoma have changed little since the 1980s, with a five-year survival rate of approximately 65-70% for patients with localised disease and a grim prognosis below 20% for those with metastatic or recurrent disease.
OST-HER2 (AOST-2121) is a HER2-targeting immunotherapy being developed by OS Therapies for patients with resected osteosarcoma. The drug targets HER2, a receptor tyrosine kinase that is overexpressed in a subset of osteosarcomas, using an immune-stimulating approach designed to activate the patient's own immune system against residual cancer cells following surgical resection. The adjuvant treatment setting — following surgical removal of the primary tumour — is the optimal context for an immune-stimulating approach, as tumour burden is lowest immediately after resection and immune activation is most likely to eliminate residual microscopic disease.
The rationale for targeting HER2 in osteosarcoma draws on the successful precedent of HER2-targeted therapy in breast and gastric cancer, where trastuzumab and pertuzumab have dramatically improved outcomes in HER2-overexpressing tumours. However, the HER2 biology in osteosarcoma differs from breast cancer, and prior attempts to use trastuzumab directly in osteosarcoma produced disappointing results, suggesting that a different approach to HER2 targeting — such as the immune stimulation strategy employed by OST-HER2 — may be necessary.
The Pre-BLA Meeting and Its Regulatory Significance
The FDA Type B pre-BLA meeting anticipated in early autumn 2026 is a pivotal step in the regulatory strategy for OST-HER2. Type B meetings are formal interactions between a pharmaceutical company and the FDA at key stages of drug development, including the pre-BLA meeting that is used to align on the adequacy of the data package, statistical methodology, and proposed labelling before the formal application is submitted.
The specific focus on statistical methodology at the pre-BLA meeting is noteworthy. In rare paediatric oncology indications like osteosarcoma, where randomised controlled trials may be challenging to conduct due to small patient populations and ethical constraints, the FDA has historically been willing to accept innovative trial designs and endpoints — including overall survival at three years as a primary or key secondary endpoint. OS Therapies' exploration of early market-entry strategies using three-year overall survival data and biomarker results suggests the company is actively discussing these alternative regulatory pathways with the FDA.
An aligned statistical methodology at the pre-BLA meeting reduces the risk of a Complete Response Letter citing inadequate or inappropriate statistical analysis — one of the most common reasons for FDA non-approval in rare oncology applications. The pre-BLA meeting is designed to surface these concerns before the formal submission, allowing OS Therapies to address any FDA concerns within the application rather than through a post-submission response.
Multi-Jurisdictional Regulatory Strategy and Capital Position
The simultaneous advancement of OST-HER2 across US (BLA), European (EMA CMAA), and Australian (Phase 3) regulatory pathways reflects a sophisticated understanding of rare disease drug development economics. In a rare paediatric cancer like osteosarcoma with only approximately 800-900 new US diagnoses annually, maximising global market access from a single clinical data package is essential for achieving the commercial returns that justify the development investment.
The EMA CMAA (Clinical Medicines Authorisation Application) filing window opening by September 30, 2026, alongside the US BLA submission reflects efficient regulatory coordination that would allow concurrent US and European review timelines. A coordinated US-EU review process could lead to simultaneous or near-simultaneous approval decisions, maximising the geographic scope of the initial commercial launch.
Management's confirmation that existing capital is sufficient to fund operations through 2027 is strategically important context for investors evaluating the regulatory calendar. Without near-term dilution risk through equity raises, shareholders can focus their attention on the scientific and regulatory binary events rather than the balance sheet management uncertainty that often accompanies small-cap biotech regulatory catalysts.
Frequently Asked Questions
Disclaimer: This article is for informational and educational purposes only and does not constitute financial or investment advice. Readers should conduct their own due diligence before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...